Similar articles for PMID: 35396319

Year	Number of Results
2009	1
2011	1
2012	1
2013	5
2014	3
2015	1
2016	9
2017	16
2018	19
2019	18
2020	18
2021	17
2022	9

1

The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial.

Tommerdahl KL, Kendrick J, Bjornstad P. Tommerdahl KL, et al. Clin J Am Soc Nephrol. 2022 Jun;17(6):905-907. doi: 10.2215/CJN.00020122. Epub 2022 Apr 8. Clin J Am Soc Nephrol. 2022. PMID: 35396319 No abstract available.

2

Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.

Hocher B, Tsuprykov O. Hocher B, et al. Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9. Nat Rev Nephrol. 2017. PMID: 28989173 No abstract available.

3

Impact of CVOTs in primary and secondary prevention of kidney disease.

De Cosmo S, Viazzi F, Piscitelli P, Leoncini G, Mirijello A, Bonino B, Pontremoli R. De Cosmo S, et al. Diabetes Res Clin Pract. 2019 Nov;157:107907. doi: 10.1016/j.diabres.2019.107907. Epub 2019 Oct 30. Diabetes Res Clin Pract. 2019. PMID: 31676332 Review.

4

GLP-1 Receptor Agonists in Diabetic Kidney Disease.

Michos ED, Tuttle KR. Michos ED, et al. Clin J Am Soc Nephrol. 2021 Oct;16(10):1578-1580. doi: 10.2215/CJN.18771220. Epub 2021 Apr 13. Clin J Am Soc Nephrol. 2021. PMID: 33849933 No abstract available.

5

Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.

Kim MK, Kim DM. Kim MK, et al. J Diabetes Investig. 2021 Jun;12(6):914-916. doi: 10.1111/jdi.13552. Epub 2021 May 7. J Diabetes Investig. 2021. PMID: 33759351 Free PMC article. Review.

6

Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.

Bailey CJ. Bailey CJ. Lancet Diabetes Endocrinol. 2020 Feb;8(2):97-99. doi: 10.1016/S2213-8587(19)30414-0. Epub 2019 Dec 13. Lancet Diabetes Endocrinol. 2020. PMID: 31843565 No abstract available.

7

Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.

Sloan LA. Sloan LA. J Diabetes. 2019 Dec;11(12):938-948. doi: 10.1111/1753-0407.12969. Epub 2019 Aug 14. J Diabetes. 2019. PMID: 31318152 Free PMC article. Review.

8

Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.

Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K. Giugliano D, et al. Diabetes Obes Metab. 2019 Aug;21(8):1790-1800. doi: 10.1111/dom.13743. Epub 2019 May 2. Diabetes Obes Metab. 2019. PMID: 30969018 Review.

9

Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?

Bellary S, Tahrani AA, Barnett AH. Bellary S, et al. Lancet Diabetes Endocrinol. 2020 Nov;8(11):870-871. doi: 10.1016/S2213-8587(20)30301-6. Epub 2020 Sep 21. Lancet Diabetes Endocrinol. 2020. PMID: 32971039 No abstract available.

10

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.

Ninčević V, Omanović Kolarić T, Roguljić H, Kizivat T, Smolić M, Bilić Ćurčić I. Ninčević V, et al. Int J Mol Sci. 2019 Nov 20;20(23):5831. doi: 10.3390/ijms20235831. Int J Mol Sci. 2019. PMID: 31757028 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed